Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

AZD6140.

Udaya S Tantry1, Kevin P Bliden, Paul A Gurbel

  • 1Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 West Belvedere Avenue, Baltimore, MD 21215, USA.

Expert Opinion on Investigational Drugs
|January 25, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TEG ® 6s Heparin Neutralization Cartridge for Hemostatic Assessment of Patients Undergoing Cardiovascular Surgery.

Anesthesiology·2025
Same author

Machine Learning Predicts Bleeding Risk in Atrial Fibrillation Patients on Direct Oral Anticoagulant.

The American journal of cardiology·2025
Same author

Reassessing the role of aspirin in patients with coronary artery disease.

Expert opinion on pharmacotherapy·2024
Same author

Can CYP2C19 genotyping improve antiplatelet therapy efficacy in real-life practice? Recent advances.

Kardiologia polska·2024
Same author

New interest in fibrinogen as an ischemic risk factor.

Journal of thrombosis and thrombolysis·2024
Same author

Milvexian: evaluating the factor XIa inhibitor for the treatment of acute coronary syndrome.

Expert opinion on pharmacotherapy·2024
Same journal

Targeting fatty acid synthase inhibitors for the treatment of acne vulgaris: what can we learn from early phase investigations.

Expert opinion on investigational drugs·2026
Same journal

Elezanumab for the treatment of spinal cord injury: assessing the clinical development journey to date.

Expert opinion on investigational drugs·2026
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
See all related articles

A new drug, AZD6140, offers superior platelet inhibition compared to clopidogrel for acute coronary syndromes. This oral P2Y12 receptor blocker shows less variability and faster action, potentially benefiting patients needing urgent surgery.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Development

Background:

  • P2Y12 receptor blockers, particularly clopidogrel, are standard oral antiplatelet therapy for acute coronary syndromes and percutaneous interventions.
  • Thienopyridine therapy presents limitations such as response variability and non-responsiveness.
  • There is a need for novel antiplatelet agents with improved efficacy and predictable responses.

Purpose of the Study:

  • To evaluate the clinical development of AZD6140, a novel oral P2Y12 receptor blocker.
  • To compare the efficacy and pharmacokinetic profile of AZD6140 against clopidogrel.
  • To assess the potential advantages of AZD6140 in specific clinical scenarios.

Main Methods:

  • Clinical trials investigating AZD6140's pharmacological properties.

Related Experiment Videos

  • Assessment of adenosine diphosphate (ADP)-induced platelet inhibition.
  • Evaluation of response variability and metabolic pathways.
  • Analysis of onset and offset of action.

    • Main Results:

    • AZD6140 demonstrates superior ADP-induced platelet inhibition compared to clopidogrel.
    • AZD6140 exhibits less response variability than clopidogrel.
    • The drug is orally available, reversible, and does not require hepatic conversion to an active metabolite.
    • AZD6140 possesses fast onset and offset of action.

    Conclusions:

    • AZD6140 represents a promising novel oral P2Y12 receptor blocker.
    • Its improved efficacy, reduced variability, and rapid action profile offer potential advantages over clopidogrel.
    • AZD6140 may be particularly beneficial for patients requiring immediate surgical intervention.